Interest of circulating tumor DNA as a biomarker for canine cancers: illustration in histiocytic sarcoma, oral malignant melanoma and multicentric lymphoma
Authors:
- Anaïs ProuteauAPAnaïs Prouteau
- Jérôme Alexandre DenisJérôme Alexandre Denis
- Pauline De FornelPFPauline De Fornel
- Edouard CadieuECEdouard Cadieu
- Thomas DerrienTDThomas Derrien
- Camille KergalCKCamille Kergal
- Nadine BotherelNBNadine Botherel
- Ronan UlvéRURonan Ulvé
- Mélanie RaultMRMélanie Rault
- Amira BouzidiABAmira Bouzidi
- Romain FrançoisRFRomain François
- Laetitia DorsoLDLaetitia Dorso
Preprint
Abstract
Circulating tumor DNA (ctDNA) has become an attractive biomarker in human oncology and may be informative in cancer-affected dogs. By performing ddPCR or PARR methods, we detected tumor-specific point mutations, copy number alterations and chromosomal rearrangements in the plasma of cancer-affected dogs. It allowed the detection of ctDNA in 2/8 (25%) oral malignant melanoma cases, 12/13 (92.3%) lymphoma cases and 21/23 (91.3%) histiocytic sarcoma (HS) cases. The value of ctDNA to diagnose HS was explored in 133 dogs including 49 with HS. In this cohort, screening recurrent PTPN11 mutations in plasma had a specificity of 98.8%, and a sensitivity between 42.8-77% according to HS clinical presentation, being higher in internal forms, especially with pulmonary location. Regarding lymphoma, the follow-up of four dogs showed that the minimal residual disease detection by targeting lymphoma-specific antigen receptor rearrangement in the plasma was concordant with the clinical evaluation. Moreover, ctDNA analysis appeared interesting to assess treatment response and to predict relapse. This study shows that ctDNA is detectable in the plasma of cancer-affected dogs and is a relevant biomarker for diagnosis and clinical follow-up. With a growing interest in integrating natural canine tumors to explore new therapies, this biomarker appears promising in comparative oncology research.Keywords
This publication has 55 references indexed in Scilit:
- Genome Aberrations in Canine Mammary Carcinomas and Their Detection in Cell-Free Plasma DNAPLOS ONE, 2013
- Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel SequencingClinical Chemistry, 2013
- Array-based comparative genomic hybridization–guided identification of reference genes for normalization of real-time quantitative polymerase chain reaction assay data for lymphomas, histiocytic sarcomas, and osteosarcomas of dogsAmerican Journal of Veterinary Research, 2012
- Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behaviorBMC Cancer, 2011
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reactionVeterinary Immunology and Immunopathology, 2008
- Cell-Free Plasma DNA as a Predictor of Outcome in Severe Sepsis and Septic ShockClinical Chemistry, 2008
- Development of the polymerase chain reaction assay based on the canine genome database for detection of monoclonality in B cell lymphomaVeterinary Immunology and Immunopathology, 2006
- Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2002
- Evaluation of a Discontinuous Treatment Protocol (VELCAP-S) for Canine LymphomaJournal of Veterinary Internal Medicine, 2001